Malaria - Pipeline Analysis - Drug Development Strategies by Therapies Employed, RoA, Targets, Mechanism of Action, and Therapeutic Modalities

PART 01: Executive summary

PART 02: Scope

• 1.1Scope of the report

PART 03: Disease overview

• 1.2Introduction
• PART 04: Regulatory framework

PART 05: Drug development landscape

• 1.3Drugs under development

PART 06: Drug development strategies

• 1.4Therapies employed
• 1.5RoA
• 1.6Therapeutic modalities
• 1.7Targets for drug development
• 1.8Mechanism of action (MoA)

PART 07: Recruitment strategies

• 1.9Geographical coverage
• 1.10Recruitment status
• 1.11Gender of participants
• 1.12Age structure
• 1.13Recruitment volume

PART 08: Key companies

• 1.14Overview

• 1.15Type of players

PART 09: Astellas Pharma, Inc.

• 1.16Overview

PART 10: Bharat Biotech Ltd.

• 1.17Overview

PART 11: Carna Biosciences, Inc.

1.18Overview

PART 12: Eisai Co. Ltd.

• 1.19Overview

PART 13: Lipotek Pty Ltd.

• 1.20Overview
• 1.21Fg115

PART 14: Merck KGaA

• 1.22Overview
• 1.23M5717

PART 15: Novartis AG

• 1.24Overview
• 1.25KAE609

PART 16: Nurex Srl

• 1.26Overview

PART 17: Sanaria, Inc.

• 1.27Overview
• 1.28PfSPZ Vaccine

PART 18: Sanofi

• 1.29Overview

PART 19: Takeda Pharmaceutical Co. Ltd.

• 1.30Overview
• 1.31DSM265
• 1.32ELQ300

PART 20: VLP Therapeutics

• 1.33Overview
• 1.34VLPM01

PART 21: Dormant molecules

PART 22: Appendix

• 1.35List of abbreviations